Effects of radiotherapy on the immune system in cancer patients
An Observational Clinical Study Plan on the Effects of Radiotherapy on the Immune System of Patients With Malignant Tumors.
This study is testing how radiotherapy affects the immune system in cancer patients to see if changes in certain immune cells can help improve treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Guangzhou First People's Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06202534 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how radiotherapy influences the immune system, specifically focusing on myeloid-derived suppressor cells (MDSCs), T cells, and extramedullary erythroid precursor cells in patients with various malignant tumors. By analyzing blood samples before and after radiotherapy, the study seeks to establish correlations between changes in these immune cells and the effectiveness of the treatment. The findings could provide insights that guide future clinical treatment strategies for cancer patients undergoing radiotherapy.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old diagnosed with specific cancers such as breast, nasopharyngeal, colorectal, cervical, lung, or head and neck cancer who require radiotherapy.
Not a fit: Patients with mental illnesses, autoimmune diseases, or severe organ complications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of how radiotherapy affects the immune response, potentially leading to improved treatment protocols for cancer patients.
How similar studies have performed: While the specific approach of this study is observational, similar studies have shown promising results in understanding the immune response to cancer treatments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Over 18 years old, diagnosed with breast cancer, nasopharyngeal cancer, colorectal cancer, cervical cancer, lung cancer, head and neck cancer and requiring radiotherapy, and the above malignant tumors have not metastasized. 2. Complete inspection information. 3. No other serious complications. 4. No infectious diseases. 5. Able and willing to take blood tests. 6. All researchers gave informed consent and signed an informed consent form, which complied with the requirements of the Medical Ethics Committee. Exclusion Criteria: 1. People with mental illness. 2. People with autoimmune system diseases. 3. Those combined with serious diseases of other organs. 4. Those with severe alcoholism and drug abuse. 5. Research subjects who voluntarily withdraw from the study.
Where this trial is running
Guangzhou, Guangdong
- GuangzhouFPH — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: yong wu, PhD
- Email: eywuyong@scut.edu.cn
- Phone: 86-13640836938
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.